Other research in mice, however, has shown that oxidative stress and inflammation brought on by aging lower NAD+ production (8). Therefore, it is likely that a number of mechanisms work together to cause individuals to lose NAD+ as they age
Chronic conditions involving persistent inflammation, incomplete tissue healing, or adaptive dysfunction respond well to the sustained gentle support that micro-dosing provides
| Risk Dimension | Evidence Quality | Severity if Realized | Practical Impact | |---|---|---|---| | Absorption interference (oral, same-time dosing) | Indirect/mechanistic | Moderate (reduced efficacy) | High: fixable with timing | | Direct chelation (glutathione binds alendronate) | None documented | Low | Low | | Pharmacodynamic antagonism (bone) | None documented | Potentially none or positive | Low | | Hepatic CYP interaction | Not applicable | None | None | | Renal clearance competition (IV glutathione) | Theoretical only | Unknown | Moderate precaution warranted | The dominant clinical concern is absorption interference, and it is entirely preventable with correct timing
Ye R, Ren A, Zhang L, et al
B cha khong 27.7mg Glutathione t nhin trong mi 100g
.jpg)
